Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proxinium plus best supportive care versus best supportive care in previously treated advanced head and neck squamous cell carcinoma
2005-005170-80Phase 3Terminated
- Sponsor
- Viventia
- Start
- Jul 2006
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of oportuzumab monatox in head and neck squamous cell carcinoma (HNSCC), sponsored by Viventia. Started Jul 2006; status: terminated.
02
Drugs
oportuzumab monatox
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2005-005170-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005170-80.